{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:01:27Z","timestamp":1785366087606,"version":"3.55.0"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","issue":"08","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Proprotein convertase subtilisin\/kexin type-9 (PCSK9) plays a crucial role in pathophysiologic processes leading to limb and cardiovascular complications in diabetes, including cholesterol homeostasis, inflammation, and endothelial oxidative stress. This study examined the association between PCSK9 levels and major adverse limb events (MALEs) in patients with type 2 diabetes mellitus (T2DM) and chronic limb-threatening ischemia (CLTI) after endovascular revascularization.<\/jats:p>\n                  <jats:p>This prospective cohort study included 147 T2DM patients with peripheral artery disease undergoing endovascular revascularization for CLTI. Clinical assessments, including PCSK9 blood levels, were performed, and patients were followed for 12 months to monitor MALEs. Logistic regression and ROC curve analyses assessed the relationship between PCSK9 and MALEs.<\/jats:p>\n                  <jats:p>During follow-up, 53 patients experienced MALEs. These patients were younger and had more severe peripheral artery disease. PCSK9 levels were significantly higher in those with MALEs (410.5\u2009ng\/mL) versus those without (360.6\u2009ng\/mL). ROC analysis showed that adding PCSK9 to cardiovascular risk factors improved MALE prediction. PCSK9 levels and Rutherford 4 category were independent risk factors for MALEs.<\/jats:p>\n                  <jats:p>Elevated PCSK9 levels are strongly associated with increased MALE risk in T2DM patients and may influence age of presentation and disease severity in CLTI. These findings highlight PCSK9 as a potential predictive biomarker and therapeutic target for vascular complications.<\/jats:p>","DOI":"10.1055\/a-2717-3194","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T23:30:11Z","timestamp":1759966211000},"page":"846-855","source":"Crossref","is-referenced-by-count":1,"title":["PCSK9 Predicts Adverse Limb Outcomes After Endovascular Revascularization in Diabetic Chronic Limb-threatening Ischemia"],"prefix":"10.1055","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7449-657X","authenticated-orcid":false,"given":"Federico","family":"Biscetti","sequence":"additional","affiliation":[{"name":"Cardiovascular Internal Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Margherita","family":"Rando","sequence":"additional","affiliation":[{"name":"Cardiovascular Internal Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Anna","family":"Nicolazzi","sequence":"additional","affiliation":[{"name":"Cardiovascular Internal Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Polito","sequence":"additional","affiliation":[{"name":"Cardiovascular Internal Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pecorini","sequence":"additional","affiliation":[{"name":"Cardiovascular Internal Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Angelini","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Iezzi","sequence":"additional","affiliation":[{"name":"Radiology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis H.","family":"Eraso","sequence":"additional","affiliation":[{"name":"Division of Vascular and Endovascular Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Dimuzio","sequence":"additional","affiliation":[{"name":"Division of Vascular and Endovascular Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Pitocco","sequence":"additional","affiliation":[{"name":"Diabetology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Massetti","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, Roma, Italy"},{"name":"Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Flex","sequence":"additional","affiliation":[{"name":"Cardiovascular Internal Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12933-022-01650-1","article-title":"Serum high mobility group box-1 levels associated with cardiovascular events after lower extremity revascularization: a prospective study of a diabetic population","volume":"21","author":"M M Rando","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/CIRCRESAHA.121.320702","article-title":"Sex differences in peripheral artery disease","volume":"130","author":"M Pabon","year":"2022","journal-title":"Circ Res"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1024\/0301-1526\/a000925","article-title":"The interrelationship between diabetes mellitus and peripheral arterial disease","volume":"50","author":"K Stoberock","year":"2021","journal-title":"Vasa"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","article-title":"Epidemiology of peripheral artery disease and polyvascular disease","volume":"128","author":"A W Aday","year":"2021","journal-title":"Circ Res"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIR.0000000000001153","article-title":"Health disparities in peripheral artery disease: a scientific statement from the American Heart Association","volume":"148","author":"M A Allison","year":"2023","journal-title":"Circulation"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIRCRESAHA.121.318258","article-title":"Contemporary medical management of peripheral artery disease","volume":"128","author":"M P Bonaca","year":"2021","journal-title":"Circ Res"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2023.08.067","article-title":"Editor's Choice\u2014European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication","volume":"67","author":"J Nordanstig","year":"2024","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.3390\/ijms22042002","article-title":"Outcomes of lower extremity endovascular revascularization: potential predictors and prevention strategies","volume":"22","author":"F Biscetti","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1161\/CIRCRESAHA.121.318261","article-title":"Advances in revascularization for peripheral artery disease: revascularization in PAD","volume":"128","author":"J A Beckman","year":"2021","journal-title":"Circ Res"},{"issue":"21","key":"ref10","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"M P Bonaca","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.115.019355","article-title":"Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients with Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2\u00b0P-TIMI 50)","volume":"133","author":"M P Bonaca","year":"2016","journal-title":"Circulation"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2337\/dc19-0408","article-title":"Inflammatory cytokines associated with failure of lower-extremity endovascular revascularization (LER): a prospective study of a population with diabetes","volume":"42","author":"F Biscetti","year":"2019","journal-title":"Diabetes Care"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12933-023-01872-x","article-title":"Development of a biomarker panel for assessing cardiovascular risk in diabetic patients with chronic limb-threatening ischemia (CLTI): a prospective study","volume":"22","author":"E Nardella","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12933-020-01123-3","article-title":"Sortilin levels correlate with major cardiovascular events of diabetic patients with peripheral artery disease following revascularization: a prospective study","volume":"19","author":"F Biscetti","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12933-019-0805-5","article-title":"Sortilin levels are associated with peripheral arterial disease in type 2 diabetic subjects","volume":"18","author":"F Biscetti","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1038\/s41598-023-33190-3","article-title":"The role of Klotho and FGF23 in cardiovascular outcomes of diabetic patients with chronic limb threatening ischemia: a prospective study","volume":"13","author":"F Biscetti","year":"2023","journal-title":"Sci Rep"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cvr\/cvz313","article-title":"PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1","volume":"116","author":"Z Ding","year":"2020","journal-title":"Cardiovasc Res"},{"issue":"22","key":"ref18","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"G G Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)","volume":"137","author":"M P Bonaca","year":"2018","journal-title":"Circulation"},{"issue":"47","key":"ref20","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1093\/eurheartj\/ehab604","article-title":"Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial","volume":"42","author":"K Oyama","year":"2021","journal-title":"Eur Heart J"},{"issue":"20","key":"ref21","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"K C Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"ref22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"J G Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"e13900","DOI":"10.1111\/eci.13900","article-title":"Serum proprotein convertase subtilisin\/Kexin type 9 and vascular disease in type 2 diabetic patients","volume":"53","author":"G Armentaro","year":"2023","journal-title":"Eur J Clin Invest"},{"issue":"08","key":"ref24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.numecd.2019.04.006","article-title":"Association of serum proprotein convertase subtilisin\/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus","volume":"29","author":"W Guo","year":"2019","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2020.11.025","article-title":"Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: the CAVASIC study","volume":"316","author":"A Kheirkhah","year":"2021","journal-title":"Atherosclerosis"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0741-5214(97)70045-4","article-title":"Recommended standards for reports dealing with lower extremity ischemia: revised version","volume":"26","author":"R B Rutherford","year":"1997","journal-title":"J Vasc Surg"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12933-020-01151-z","article-title":"Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study","volume":"19","author":"F Biscetti","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"S395","DOI":"10.1097\/01.RVI.0000094613.61428.a9","article-title":"Reporting standards for clinical evaluation of new peripheral arterial revascularization devices","volume":"14","author":"D Sacks","year":"2003","journal-title":"J Vasc Interv Radiol"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jvs.2021.08.096","article-title":"Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial","volume":"75","author":"N Govsyeyev","year":"2022","journal-title":"J Vasc Surg"},{"issue":"13","key":"ref32","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCULATIONAHA.115.018531","article-title":"Circulating proprotein convertase subtilisin\/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors","volume":"133","author":"K Leander","year":"2016","journal-title":"Circulation"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/eurheartj\/ehv568","article-title":"Plasma proprotein convertase subtilisin\/kexin type 9 levels and the risk of first cardiovascular events","volume":"37","author":"P M Ridker","year":"2016","journal-title":"Eur Heart J"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1038\/s41467-024-46336-2","article-title":"PCSK9 stimulates Syk, PKC\u03b4, and NF-\u03baB, leading to atherosclerosis progression independently of LDL receptor","volume":"15","author":"D Shin","year":"2024","journal-title":"Nat Commun"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","article-title":"PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study","volume":"248","author":"J M Cheng","year":"2016","journal-title":"Atherosclerosis"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (proprotein convertase subtilisin\/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36","volume":"143","author":"Z Qi","year":"2021","journal-title":"Circulation"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2717-3194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:57:12Z","timestamp":1785365832000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2717-3194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":35,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2026,7,29]]},"published-print":{"date-parts":[[2026,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2717-3194","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,8]]},"published":{"date-parts":[[2025,10,8]]}}}